Cargando…

A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors

BACKGROUND: To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of irinotecan administered in combination with vincristine, temozolomide and bevacizumab in children with refractory solid tumors. METHODS: The study design included two dose levels (DL) of irinotecan given in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Venkatramani, Rajkumar, Malogolowkin, Marcio, Davidson, Tom B., May, William, Sposto, Richard, Mascarenhas, Leo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718768/ https://www.ncbi.nlm.nih.gov/pubmed/23894304 http://dx.doi.org/10.1371/journal.pone.0068416

Ejemplares similares

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults
por: Ju, Hee Young, et al.
Publicado: (2022)

A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation
por: Metts, Jonathan L., et al.
Publicado: (2022)

DIPG-12. OUTCOMES IN PEDIATRIC MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS UTILIZING TEMOZOLOMIDE, BEVACIZUMAB, AND IRINOTECAN
por: Reel, Sarah, et al.
Publicado: (2023)

Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

Activity of irinotecan and temozolomide in the presence of O(6)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
por: Cai, W, et al.
Publicado: (2010)

Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
por: Casanova, Michela, et al.
Publicado: (2023)

Correlation between maternal and childhood VitB12, folic acid and ferritin levels
por: Zeeshan, Fatima, et al.
Publicado: (2017)

Linagliptin treatment is associated with altered cobalamin (VitB12) homeostasis in mice and humans
por: Tammen, Harald, et al.
Publicado: (2023)

A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas
por: Russo, Ida, et al.
Publicado: (2020)

Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study
por: Lu, Guangrong, et al.
Publicado: (2019)

LINC-05. Successful response to bevacizumab/irinotecan/temozolomide in a progressive choroid plexus carcinoma: A case report
por: del Campo, Regina Navarro-Martin, et al.
Publicado: (2022)

Combined effect of propranolol, vincristine and bevacizumab on HUVECs and BJ cells
por: Bota, Mădălina, et al.
Publicado: (2019)

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
por: DuBois, S G, et al.
Publicado: (2015)

Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta‐analysis
por: Allen‐Rhoades, Wendy, et al.
Publicado: (2023)

Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma?
por: Heng, Marie Amélie, et al.
Publicado: (2016)

Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy
por: Zhang, Jicai, et al.
Publicado: (2018)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model
por: Igarashi, Kentaro, et al.
Publicado: (2017)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
por: Mesti, Tanja, et al.
Publicado: (2015)

Irinotecan and vincristine for the treatment of refractory desmoplastic small round cell tumor in a developing country: a case report
por: Ambar, Natalia Brenneken Duarte, et al.
Publicado: (2019)

SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma
por: Chugh, Rashmi, et al.
Publicado: (2020)

Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review
por: Hafazalla, Karim, et al.
Publicado: (2018)

AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes
por: Zhang, Shuai, et al.
Publicado: (2021)

Complete Radiologic Response in an Anaplastic Oligodendroglioma Treated with Temozolomide and Bevacizumab
por: Katz, Artur, et al.
Publicado: (2009)

An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas
por: Laffaire, Julien, et al.
Publicado: (2014)

Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan
por: Almubarak, Mohammed, et al.
Publicado: (2008)

Temozolomide and cisplatin in relapsed/refractory acute leukemia
por: Seiter, Karen, et al.
Publicado: (2009)

Temozolomide: COVID-19 relapse: case report
Publicado: (2022)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab
por: Tamura, Ryota, et al.
Publicado: (2020)

ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma
por: Shi, Ying, et al.
Publicado: (2021)

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx(®)) or vincristine
por: Verreault, Maite, et al.
Publicado: (2011)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Genetic Polymorphisms Associated with Vincristine Pharmacokinetics and Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology Patients
por: van de Velde, Mirjam E., et al.
Publicado: (2022)

Relapsed Rhabdomyosarcoma
por: Heske, Christine M., et al.
Publicado: (2021)

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas
por: Coyne, Geraldine O'Sullivan, et al.
Publicado: (2020)

Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two‐Cohort, Phase Ib/II Trial
por: Xu, Jie, et al.
Publicado: (2021)

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
por: Shields, Lisa BE, et al.
Publicado: (2013)

Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma
por: Chen, Zhaoyan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4sknjqem6331e70rf5veilv9to